Blue Oak Delivers New Drugs for Patients by Focusing on Four Key Capabilities

As interest in mental health – and neuroscience and neuropsychiatry in particular – increase, Blue Oak is well-positioned to help patients and their families. We are developing a pipeline of research and clinical programs that treat major brain disorders, including bipolar depression, schizophrenia and geriatric psychosis. Our circuit-repair strategy has already proven to be fundamentally better than the past historical strategy of modulating single-drug targets.

Thomas H. Large, Ph.D. President and CEO
Kerry L. Spear, Ph.D. Chief Science Officer

Leading Experts in CNS Drug R&D

15+ YEAR PARTNERSHIP WITH 15+ IND/CTAS

Our founders, Thomas Large and Kerry Spear, are internationally-recognized experts in translational medicine, neuropharmacology and medicinal chemistry. Both have held leadership roles at leading pharmaceutical companies like Eli Lilly and Sunovion.

MEET THE TEAM

News from Blue Oak

Nimh Award

Blue Oak awarded a $2.9M Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health (NIMH) to develop next generation drugs for bipolar disorder.

Read

Press Release

US startup Blue Oak Pharma has joined a lengthening list of companies turning to Exscientia of the UK for its expertise in applying artificial intelligence to drug discovery.

October 14, 2020 US startup Blue Oak Pharma has joined

Fund Raising

Viva Biotech Holdings leads Series A funding round, alongside ShangPharma Innovation and JMCR Family Partners, to advance the Blue Oak R&D pipeline in psychiatric drugs.

Publication

SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Actions

Presentation

Blue Oak delivers a podium presentation at the Keystone Meeting on Phenotypic Drug Discovery describing a systems neurobiology approach to discovering the next generation of drugs for bipolar depression.

Nimh Award

Blue Oak awarded a $900,000 Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health (NIMH) to develop next generation drugs for bipolar disorder.

NIMH Funding

Blue Oak has received sustained funding from the National Institute of Mental Health (NIMH) to support drug discovery and clinical development.

Key Partnerships

Shang Pharma innovation
Exscientia
Sprout BioVentures
IVA Biotech
JMCR Family Office
PDSP
Porsolt
PsychoGenics
SB Drug Discovery
EuMentis

Join Our Fight Against Brain Disorders

For investment or partnership opportunities or to learn more about our clinical programs, contact our team today.

CONTACT US
caret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-square